The MRSAid photodisinfection system is designed to reduce Methicillin-resistant Staphylococcus aureus (MRSA) colonization of the anterior nasal passages, the company said.
Carolyn Cross, chairman and CEO of Ondine, said: “Ondine’s non-antibiotic MRSAid system is designed to block carriage of these resistant microbes before transmission can occur between patients, visitors and healthcare workers.
“The commercialization plan for the MRSAid system includes continued in-hospital evaluations on high-level MRSA carriers, development of the US regulatory pathway and establishment of distribution partners.”